VIVE SEC Filings - Viveve Medical, Inc.- Annual Report, Proxy Statement, Prospectus

Basic Stats

CIK

879682

SEC Filings

All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis. These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Viveve Medical, Inc.

SEC Filings (Chronological Order)

This page provides a complete, chronological list of SEC Filings, excluding ownership filings which we provide elsewhere.

February 6, 2023	15-12G	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 15 CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 15 CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13 AND 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. 001-11388 Commission File Number VIVEVE MEDICAL, INC. (Exact name of registrant as specified in its
January 27, 2023	POS AM	As filed with the Securities and Exchange Commission on January 26, 2023. As filed with the Securities and Exchange Commission on January 26, 2023. Registration No. 333-233639 Registration No. 333-239279 Registration No. 333-239280 Registration No. 333-251517 Registration No. 333-252091 Registration No. 333-254926 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 POST-EFFECTIVE AMENDMENT NO. 1 TO: Form S-1 Registration No. 333-233639 Form S-1 Regis
January 27, 2023	POS AM	As filed with the Securities and Exchange Commission on January 26, 2023. As filed with the Securities and Exchange Commission on January 26, 2023. Registration No. 333-233639 Registration No. 333-239279 Registration No. 333-239280 Registration No. 333-251517 Registration No. 333-252091 Registration No. 333-254926 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 POST-EFFECTIVE AMENDMENT NO. 1 TO: Form S-1 Registration No. 333-233639 Form S-1 Regis
January 27, 2023	S-8 POS	As filed with the Securities and Exchange Commission on January 26, 2023. As filed with the Securities and Exchange Commission on January 26, 2023. Registration No. 333-127770 Registration No. 333-153535 Registration No. 333-206041 Registration No. 333-213363 Registration No. 333-220833 Registration No. 333-226152 Registration No. 333-237279 Registration No. 333-254916 Registration No. 333-257649 Registration No. 333-262007 UNITED STATES SECURITIES AND EXCHANGE COMMISSI
January 27, 2023	S-8 POS	As filed with the Securities and Exchange Commission on January 26, 2023. As filed with the Securities and Exchange Commission on January 26, 2023. Registration No. 333-127770 Registration No. 333-153535 Registration No. 333-206041 Registration No. 333-213363 Registration No. 333-220833 Registration No. 333-226152 Registration No. 333-237279 Registration No. 333-254916 Registration No. 333-257649 Registration No. 333-262007 UNITED STATES SECURITIES AND EXCHANGE COMMISSI
January 27, 2023	POS AM	As filed with the Securities and Exchange Commission on January 26, 2023. As filed with the Securities and Exchange Commission on January 26, 2023. Registration No. 333-233639 Registration No. 333-239279 Registration No. 333-239280 Registration No. 333-251517 Registration No. 333-252091 Registration No. 333-254926 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 POST-EFFECTIVE AMENDMENT NO. 1 TO: Form S-1 Registration No. 333-233639 Form S-1 Regis
January 27, 2023	S-8 POS	As filed with the Securities and Exchange Commission on January 26, 2023. As filed with the Securities and Exchange Commission on January 26, 2023. Registration No. 333-127770 Registration No. 333-153535 Registration No. 333-206041 Registration No. 333-213363 Registration No. 333-220833 Registration No. 333-226152 Registration No. 333-237279 Registration No. 333-254916 Registration No. 333-257649 Registration No. 333-262007 UNITED STATES SECURITIES AND EXCHANGE COMMISSI
January 27, 2023	S-8 POS	As filed with the Securities and Exchange Commission on January 26, 2023. As filed with the Securities and Exchange Commission on January 26, 2023. Registration No. 333-127770 Registration No. 333-153535 Registration No. 333-206041 Registration No. 333-213363 Registration No. 333-220833 Registration No. 333-226152 Registration No. 333-237279 Registration No. 333-254916 Registration No. 333-257649 Registration No. 333-262007 UNITED STATES SECURITIES AND EXCHANGE COMMISSI
January 27, 2023	S-8 POS	As filed with the Securities and Exchange Commission on January 26, 2023. S-8 POS 1 vive20230125es8pos.htm FORM S-8 POS As filed with the Securities and Exchange Commission on January 26, 2023. Registration No. 333-127770 Registration No. 333-153535 Registration No. 333-206041 Registration No. 333-213363 Registration No. 333-220833 Registration No. 333-226152 Registration No. 333-237279 Registration No. 333-254916 Registration No. 333-257649 Registration No. 333-262007
January 27, 2023	S-8 POS	As filed with the Securities and Exchange Commission on January 26, 2023. As filed with the Securities and Exchange Commission on January 26, 2023. Registration No. 333-127770 Registration No. 333-153535 Registration No. 333-206041 Registration No. 333-213363 Registration No. 333-220833 Registration No. 333-226152 Registration No. 333-237279 Registration No. 333-254916 Registration No. 333-257649 Registration No. 333-262007 UNITED STATES SECURITIES AND EXCHANGE COMMISSI
January 27, 2023	S-8 POS	As filed with the Securities and Exchange Commission on January 26, 2023. As filed with the Securities and Exchange Commission on January 26, 2023. Registration No. 333-127770 Registration No. 333-153535 Registration No. 333-206041 Registration No. 333-213363 Registration No. 333-220833 Registration No. 333-226152 Registration No. 333-237279 Registration No. 333-254916 Registration No. 333-257649 Registration No. 333-262007 UNITED STATES SECURITIES AND EXCHANGE COMMISSI
January 27, 2023	RW	Viveve Medical, Inc. 345 Inverness Drive South Building B, Suite 250 Englewood, Colorado 80112 RW 1 vive20230125rw.htm FORM RW Viveve Medical, Inc. 345 Inverness Drive South Building B, Suite 250 Englewood, Colorado 80112 January 26, 2023 Via EDGAR Transmission United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Re: Viveve Medical, Inc. Registration Statement on Form S-1 (File No. 333-268311) Ladies and Gentlemen: Pursua
January 27, 2023	POS AM	As filed with the Securities and Exchange Commission on January 26, 2023. As filed with the Securities and Exchange Commission on January 26, 2023. Registration No. 333-233639 Registration No. 333-239279 Registration No. 333-239280 Registration No. 333-251517 Registration No. 333-252091 Registration No. 333-254926 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 POST-EFFECTIVE AMENDMENT NO. 1 TO: Form S-1 Registration No. 333-233639 Form S-1 Regis
January 27, 2023	S-8 POS	As filed with the Securities and Exchange Commission on January 26, 2023. As filed with the Securities and Exchange Commission on January 26, 2023. Registration No. 333-127770 Registration No. 333-153535 Registration No. 333-206041 Registration No. 333-213363 Registration No. 333-220833 Registration No. 333-226152 Registration No. 333-237279 Registration No. 333-254916 Registration No. 333-257649 Registration No. 333-262007 UNITED STATES SECURITIES AND EXCHANGE COMMISSI
January 27, 2023	POS AM	As filed with the Securities and Exchange Commission on January 26, 2023. As filed with the Securities and Exchange Commission on January 26, 2023. Registration No. 333-257648 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 POST-EFFECTIVE AMENDMENT NO. 1 TO: Form S-3 Registration No. 333-257648 UNDER THE SECURITIES ACT OF 1933 VIVEVE MEDICAL, INC. (Exact name of registrant as specified in its charter) Delaware 04-3153858 (State or other jurisdict
January 27, 2023	S-8 POS	As filed with the Securities and Exchange Commission on January 26, 2023. As filed with the Securities and Exchange Commission on January 26, 2023. Registration No. 333-127770 Registration No. 333-153535 Registration No. 333-206041 Registration No. 333-213363 Registration No. 333-220833 Registration No. 333-226152 Registration No. 333-237279 Registration No. 333-254916 Registration No. 333-257649 Registration No. 333-262007 UNITED STATES SECURITIES AND EXCHANGE COMMISSI
January 27, 2023	S-8 POS	As filed with the Securities and Exchange Commission on January 26, 2023. As filed with the Securities and Exchange Commission on January 26, 2023. Registration No. 333-127770 Registration No. 333-153535 Registration No. 333-206041 Registration No. 333-213363 Registration No. 333-220833 Registration No. 333-226152 Registration No. 333-237279 Registration No. 333-254916 Registration No. 333-257649 Registration No. 333-262007 UNITED STATES SECURITIES AND EXCHANGE COMMISSI
January 27, 2023	POS AM	As filed with the Securities and Exchange Commission on January 26, 2023. As filed with the Securities and Exchange Commission on January 26, 2023. Registration No. 333-233639 Registration No. 333-239279 Registration No. 333-239280 Registration No. 333-251517 Registration No. 333-252091 Registration No. 333-254926 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 POST-EFFECTIVE AMENDMENT NO. 1 TO: Form S-1 Registration No. 333-233639 Form S-1 Regis
January 27, 2023	POS AM	As filed with the Securities and Exchange Commission on January 26, 2023. POS AM 1 vive20230125dposam.htm FORM POS AM As filed with the Securities and Exchange Commission on January 26, 2023. Registration No. 333-233639 Registration No. 333-239279 Registration No. 333-239280 Registration No. 333-251517 Registration No. 333-252091 Registration No. 333-254926 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 POST-EFFECTIVE AMENDMENT NO. 1 TO: Form S-
January 18, 2023	8-K	Current Report UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 17, 2023 VIVEVE MEDICAL, INC. (Exact name of registrant as specified in its charter) Delaware 1-11388 04-3153858 (State or other jurisdiction of incorporation) (Commission Fil
January 17, 2023	EX-99.1	Viveve Announces Topline Results from Pivotal U.S. PURSUIT Trial for Treating Female Stress Urinary Incontinence Study's primary efficacy endpoint was not achieved at 12 months post-treatment Company has implemented a reduction in force Company will Exhibit 99.1 Viveve Announces Topline Results from Pivotal U.S. PURSUIT Trial for Treating Female Stress Urinary Incontinence Study's primary efficacy endpoint was not achieved at 12 months post-treatment Company has implemented a reduction in force Company will seek strategic alternatives and will be delisted from Nasdaq ENGLEWOOD, CO – January 17, 2023 – Viveve Medical, Inc. (NASDAQ: VIVE), a me
January 17, 2023	8-K	Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Costs Associated with Exit or Disposal Activities, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 14, 2023 VIVEVE MEDICAL, INC. (Exact name of registrant as specified in its charter) Delaware 1-11388 04-3153858 (State or other jurisdiction of incorporation) (Commission Fil
December 15, 2022	EX-99.1	Viveve Announces Completion of Pivotal U.S. PURSUIT Trial for Female Stress Urinary Incontinence with Final 12-month Follow-up Visits Concluded Topline results of the 12-month primary efficacy endpoint anticipated in January 2023 Positive results may Exhibit 99.1 Viveve Announces Completion of Pivotal U.S. PURSUIT Trial for Female Stress Urinary Incontinence with Final 12-month Follow-up Visits Concluded Topline results of the 12-month primary efficacy endpoint anticipated in January 2023 Positive results may support a de novo marketing application for a new U.S. indication for treatment of stress urinary incontinence in women ENGLEWOOD, CO –
December 15, 2022	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 15, 2022 VIVEVE MEDICAL, UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 15, 2022 VIVEVE MEDICAL, INC. (Exact name of registrant as specified in its charter) Delaware 1-11388 04-3153858 (State or other jurisdiction of incorporation) (Commission Fi
December 6, 2022	S-1/A	As filed with the Securities and Exchange Commission on December 6, 2022 As filed with the Securities and Exchange Commission on December 6, 2022 Registration No.
December 2, 2022	8-K	Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 29, 2022 VIVEVE MEDICAL, INC. (Exact name of registrant as specified in its charter) Delaware 1-11388 04-3153858 (State or other jurisdiction of incorporation) (Commission Fi
December 1, 2022	EX-99.1	Viveve Announces Issuance of Second U.S. Method Patent for Treating Female Stress Urinary Incontinence Patent further strengthens Viveve's novel dual-energy technology intellectual property portfolio as company plans for completion of pivotal PURSUIT Exhibit 99.1 Viveve Announces Issuance of Second U.S. Method Patent for Treating Female Stress Urinary Incontinence Patent further strengthens Viveve's novel dual-energy technology intellectual property portfolio as company plans for completion of pivotal PURSUIT clinical trial ENGLEWOOD, CO – December 1, 2022 - Viveve Medical, Inc. (NASDAQ: VIVE), a medical technology company focused on women's h
December 1, 2022	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 1, 2022 VIVEVE MEDICAL, UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 1, 2022 VIVEVE MEDICAL, INC. (Exact name of registrant as specified in its charter) Delaware 1-11388 04-3153858 (State or other jurisdiction of incorporation) (Commission Fil
November 23, 2022	8-K	Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 18, 2022 VIVEVE MEDICAL, INC. (Exact name of registrant as specified in its charter) Delaware 1-11388 04-3153858 (State or other jurisdiction of incorporation) (Commission Fi
November 14, 2022	DEL AM	Viveve Medical, Inc. 345 Inverness Drive South Building B, Suite 250 Englewood, Colorado 80112 Viveve Medical, Inc. 345 Inverness Drive South Building B, Suite 250 Englewood, Colorado 80112 November 14, 2022 Via EDGAR Transmission United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Re: Viveve Medical, Inc. Registration Statement on Form S-1 (File No. 333-268311) Ladies and Gentlemen: Reference is made to the registration
November 10, 2022	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 1-11388 VIVEVE M
November 10, 2022	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 10, 2022 VIVEVE MEDICAL, UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 10, 2022 VIVEVE MEDICAL, INC. (Exact name of registrant as specified in its charter) Delaware 1-11388 04-3153858 (State or other jurisdiction of incorporation) (Commission Fi
November 10, 2022	EX-FILING FEES	Filing Fee Table^ Exhibit 107 Calculation of Filing Fee Tables Form S-1 (Form Type) Viveve Medical, Inc.
November 10, 2022	EX-99.1	Viveve Reports Third Quarter 2022 Financial Results and Provides Corporate Update Total revenue of $1.7 million in Q3 including sale of 3,100 disposable treatment tips PURSUIT clinical trial completion expected by year-end Conference call to be hoste Exhibit 99.1 Viveve Reports Third Quarter 2022 Financial Results and Provides Corporate Update Total revenue of $1.7 million in Q3 including sale of 3,100 disposable treatment tips PURSUIT clinical trial completion expected by year-end Conference call to be hosted by Company at 5:00 PM ET today ENGLEWOOD, CO – November 10, 2022 – Viveve Medical, Inc. (NASDAQ: VIVE), a medical technology company fo
November 10, 2022	S-1	Power of Attorney^ (included on signature page hereto) As filed with the Securities and Exchange Commission on November 10, 2022 Registration No.
October 4, 2022	8-K	Regulation FD Disclosure UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 4, 2022 VIVEVE MEDICAL, INC. (Exact name of registrant as specified in its charter) Delaware 1-11388 04-3153858 (State or other jurisdiction of incorporation) (Commission File
October 4, 2022	EX-99.1	Viveve Announces Notice of Allowance for Second U.S. Method Patent for Treating Female Stress Urinary Incontinence Patent issuance further strengthens Viveve’s intellectual property portfolio for the treatment of female stress urinary incontinence Exhibit 99.1 Viveve Announces Notice of Allowance for Second U.S. Method Patent for Treating Female Stress Urinary Incontinence Patent issuance further strengthens Viveve?s intellectual property portfolio for the treatment of female stress urinary incontinence ENGLEWOOD, CO ? October 4, 2022 - Viveve Medical, Inc. (NASDAQ: VIVE), a medical technology company focused on women's health and the treat
September 27, 2022	8-K	Regulation FD Disclosure UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 27, 2022 VIVEVE MEDICAL, INC. (Exact name of registrant as specified in its charter) Delaware 1-11388 04-3153858 (State or other jurisdiction of incorporation) (Commission F
September 27, 2022	EX-99.1	Viveve Launches Rebranding Initiative to Reflect Focus on Treatment of Female Stress Urinary Incontinence in Anticipation of U.S. Pivotal PURSUIT Trial Readout New branding reflects Company’s vision to be the leader in the treatment of Stress Urinary Exhibit 99.1 Viveve Launches Rebranding Initiative to Reflect Focus on Treatment of Female Stress Urinary Incontinence in Anticipation of U.S. Pivotal PURSUIT Trial Readout New branding reflects Company?s vision to be the leader in the treatment of Stress Urinary Incontinence in Women Completion of PURSUIT follow-up visits anticipated by the end of 2022 with topline results expected shortly therea
September 26, 2022	CORRESP	Viveve Medical, Inc. 345 Inverness Drive South Building B, Suite 250 Englewood, Colorado 80112 Viveve Medical, Inc. 345 Inverness Drive South Building B, Suite 250 Englewood, Colorado 80112 September 26, 2022 Via EDGAR Transmission United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attention: Jane Park Re: Viveve Medical, Inc. Acceleration Request for Registration Statement on Form S-3 File No. 333-257648, Filed July 2,
September 23, 2022	EX-FILING FEES	Filing Fee Table Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) Viveve Medical, Inc.
September 23, 2022	S-3/A	As filed with the Securities and Exchange Commission on September 23, 2022. As filed with the Securities and Exchange Commission on September 23, 2022. Registration No. 333-257648 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Amendment No. 1 to FORM S-3 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 VIVEVE MEDICAL, INC. (Exact name of registrant as specified in its charter) Delaware 04-3153858 (State or other jurisdiction of incorporatio
September 22, 2022	EX-99.1	Viveve to Participate in Ladenburg Thalmann Healthcare Conference Exhibit 99.1 Viveve to Participate in Ladenburg Thalmann Healthcare Conference ENGLEWOOD, CO ? September 22, 2022 - Viveve Medical, Inc. (NASDAQ: VIVE), a medical technology company focused on women's health and the treatment of stress urinary incontinence (SUI), today announced that Scott Durbin, chief executive officer, will participate in the Ladenburg Thalmann Healthcare Conference, September
September 22, 2022	8-K	Regulation FD Disclosure UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 22, 2022 VIVEVE MEDICAL, INC. (Exact name of registrant as specified in its charter) Delaware 1-11388 04-3153858 (State or other jurisdiction of incorporation) (Commission F
September 15, 2022	8-K	Regulation FD Disclosure UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 15, 2022 VIVEVE MEDICAL, INC. (Exact name of registrant as specified in its charter) Delaware 1-11388 04-3153858 (State or other jurisdiction of incorporation) (Commission F
September 15, 2022	EX-99.1	Viveve to Participate in Alliance Global Partners Virtual MedTech Conference Exhibit 99.1 Viveve to Participate in Alliance Global Partners Virtual MedTech Conference ENGLEWOOD, CO ? September 15, 2022 - Viveve Medical, Inc. (NASDAQ: VIVE), a medical technology company focused on women's health and the treatment of stress urinary incontinence (SUI), today announced that Scott Durbin, chief executive officer, will participate in the Alliance Global Partners Virtual MedTech
September 1, 2022	EX-99.1	Viveve to Participate in H.C. Wainwright 24th Annual Global Investment Conference Exhibit 99.1 Viveve to Participate in H.C. Wainwright 24th Annual Global Investment Conference ENGLEWOOD, CO ? September 1, 2022 - Viveve Medical, Inc. (NASDAQ: VIVE), a medical technology company focused on women's health and the treatment of stress urinary incontinence (SUI), today announced that Scott Durbin, chief executive officer, will participate in the H.C. Wainwright 24th Annual Global In
September 1, 2022	8-K	Regulation FD Disclosure UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 1, 2022 VIVEVE MEDICAL, INC. (Exact name of registrant as specified in its charter) Delaware 1-11388 04-3153858 (State or other jurisdiction of incorporation) (Commission Fi
August 11, 2022	EX-99.1	Viveve Reports Second Quarter 2022 Financial Results and Provides Corporate Update Total revenue of $1.8 million in Q2 including sale of 2,850 disposable treatment tips PURSUIT clinical trial follow-up visit completion anticipated by year end Confere Exhibit 99.1 Viveve Reports Second Quarter 2022 Financial Results and Provides Corporate Update Total revenue of $1.8 million in Q2 including sale of 2,850 disposable treatment tips PURSUIT clinical trial follow-up visit completion anticipated by year end Conference call to be hosted by Company at 5:00 PM ET today ENGLEWOOD, CO ? August 11, 2022 ? Viveve Medical, Inc. (NASDAQ: VIVE), a medical tec
August 11, 2022	8-K	Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 11, 2022 VIVEVE MEDICAL, INC. (Exact name of registrant as specified in its charter) Delaware 1-11388 04-3153858 (State or other jurisdiction of incorporation) (Commission File
August 11, 2022	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 1-11388 VIVEVE MEDICA
July 12, 2022	8-K	Regulation FD Disclosure UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 12, 2022 VIVEVE MEDICAL, INC. (Exact name of registrant as specified in its charter) Delaware 1-11388 04-3153858 (State or other jurisdiction of incorporation) (Commission File N
July 12, 2022	EX-99.1	Viveve Announces Expansion of IP Portfolio with Patent Issuance in Taiwan Exhibit 99.1 Viveve Announces Expansion of IP Portfolio with Patent Issuance in Taiwan Englewood, CO ? July 12, 2022 ? Viveve Medical, Inc. (NASDAQ: VIVE), a medical technology company focused on women?s health and the treatment of stress urinary incontinence (SUI), today announced that the Taiwan Intellectual Property Office (TIPO) recently issued Taiwan Patent No. I766557 for Viveve?s dual-energ
June 3, 2022	8-K	Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): May 31, 2022 VIVEVE MEDICAL, INC. (Exact name of registrant as specified in its charter) Delaware 1-11388 04-3153858 (State or other jurisdiction of incorporation) (Commission File Nu
May 17, 2022	EX-99.1	Viveve to Participate in H.C. Wainwright Global Investment Conference Exhibit 99.1 Viveve to Participate in H.C. Wainwright Global Investment Conference ENGLEWOOD, CO ? May 17, 2022 - Viveve Medical, Inc. (NASDAQ: VIVE), a medical technology company focused on women's health, today announced that Scott Durbin, chief executive officer, will participate in the H.C. Wainwright Global Investment Conference, May 23 - 26, 2022. Mr. Durbin will deliver the Viveve corporate
May 17, 2022	8-K	Regulation FD Disclosure UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 17, 2022 VIVEVE MEDICAL, INC. (Exact name of registrant as specified in its charter) Delaware 1-11388 04-3153858 (State or other jurisdiction of incorporation) (Commission File Nu
May 12, 2022	EX-99.1	Viveve Reports First Quarter 2022 Financial Results and Provides Corporate Update Total revenue of $1.6 million in Q1 including sale of 2,750 consumable treatment tips PURSUIT trial top-line results anticipated at end of 2022 Conference call to be ho Exhibit 99.1 Viveve Reports First Quarter 2022 Financial Results and Provides Corporate Update Total revenue of $1.6 million in Q1 including sale of 2,750 consumable treatment tips PURSUIT trial top-line results anticipated at end of 2022 Conference call to be hosted by Company at 5:00 PM ET today ENGLEWOOD, CO ? May 12, 2022 ? Viveve Medical, Inc. (NASDAQ: VIVE), a medical technology company focu
May 12, 2022	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 1-11388 VIVEVE MEDIC
May 12, 2022	8-K	Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 12, 2022 VIVEVE MEDICAL, INC. (Exact name of registrant as specified in its charter) Delaware 1-11388 04-3153858 (State or other jurisdiction of incorporation) (Commission File Nu
May 12, 2022	EX-10.1	Fifth Amended and Restated Viveve Medical, Inc. Independent Director Compensation Policy. Exhibit 10.1 FIFTH AMENDED AND RESTATED VIVEVE MEDICAL, INC. INDEPENDENT DIRECTOR COMPENSATION POLICY The Board of Directors (the ?Board?) of Viveve Medical, Inc. (the ?Company?) has adopted the following amended and restated compensation policy (this ?Policy?), effective as of April 12, 2022 (the ?Effective Date?) for directors of the Company who are not employees of the Company or any parent or
May 9, 2022	8-K	Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 3, 2022 VIVEVE MEDICAL, INC. (Exact name of registrant as specified in its charter) Delaware 1-11388 04-3153858 (State or other jurisdiction of incorporation) (Commission File Num
March 17, 2022	EX-99.1	Viveve Reports Full Year 2021 Financial Results and Provides Corporate Update Reported total revenue for year end 2021 of $6.4 million representing 17% year-over-year growth Enrollment completed in U.S. pivotal PURSUIT trial for stress urinary incont Exhibit 99.1 Viveve Reports Full Year 2021 Financial Results and Provides Corporate Update Reported total revenue for year end 2021 of $6.4 million representing 17% year-over-year growth Enrollment completed in U.S. pivotal PURSUIT trial for stress urinary incontinence and 12-month post treatment follow-up visits underway PURSUIT top-line results anticipated at end of 2022 Conference call to be ho
March 17, 2022	EX-3.9	Certificate of Elimination of Series C Preferred Stock(40) Exhibit 3.9 CERTIFICATE OF ELIMINATION OF SERIES C CONVERTIBLE PREFERRED STOCK, A SERIES OF PREFERRED STOCK OF VIVEVE MEDICAL, INC. (Pursuant to Section 151(g) of the Delaware General Corporation Law) VIVEVE MEDICAL, INC., a corporation organized and existing under the laws of the State of Delaware (the ?Corporation?), does hereby certify that the following resolutions respecting Series C Converti
March 17, 2022	10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K (Mark One) ? ANNUAL REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 or ? TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from .
March 17, 2022	DEF 14A	Schedule 14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Defin
March 17, 2022	EX-4.20	Description of Securities* Exhibit 4.20 DESCRIPTION OF THE REGISTRANT?S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 As of December 31, 2021 Viveve Medical, Inc. (?Viveve?) has one class of securities registered under Section 12 of the Securities Exchange Act of 1934, as amended (the ?Exchange Act?): common stock, par value $0.0001 per share (the ?common stock?). DESCRIPTION OF COMMON
March 17, 2022	8-K	Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 17, 2022 VIVEVE MEDICAL, INC. (Exact name of registrant as specified in its charter) Delaware 1-11388 04-3153858 (State or other jurisdiction of incorporation) (Commission File
February 4, 2022	SC 13G/A	VIVE / Viveve Medical Inc / Hudson Bay Capital Management LP - VIVE 13G/A Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 2)* Viveve Medical, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 92852W501 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant
January 21, 2022	8-K	Current Report UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 18, 2022 VIVEVE MEDICAL, INC. (Exact name of registrant as specified in its charter) Delaware 1-11388 04-3153858 (State or other jurisdiction of incorporation) (Commission Fil
January 21, 2022	EX-10.1	Form of Retention Bonus Agreement (39) Exhibit 10.1 January , 2022 BY EMAIL [NAME] Re: Retention Bonus Opportunity Dear : At this time, the Company considers it to be in the best interests of Viveve Medical, Inc. (the ?Company?) to promote and preserve the employment of certain employees (the ?Specified Employees?). You are a Specified Employee and, therefore, the Company?s has determined that appropriate steps should be taken to reinf
January 18, 2022	SC 13G/A	VIVE / Viveve Medical Inc / Empery Asset Management, LP - VIVEVE MEDICAL, INC. Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* Viveve Medical, Inc. (Name of Issuer) Common Stock, par value $0.0001 (Title of Class of Securities) 92852W501 (CUSIP Number) December 31, 2021 (Date of event which requires filing of this statement) Check the appropriate box to designate the rule pursuant to which th
January 5, 2022	S-8	As filed with the Securities and Exchange Commission on January 4, 2022 As filed with the Securities and Exchange Commission on January 4, 2022 Registration No.
December 14, 2021	EX-99.1	Viveve Announces Completion of Full Enrollment in Pivotal U.S. PURSUIT Trial for Stress Urinary Incontinence Major milestone achieved in Company’s advance toward a new U.S. SUI indication Exhibit 99.1 Viveve Announces Completion of Full Enrollment in Pivotal U.S. PURSUIT Trial for Stress Urinary Incontinence Major milestone achieved in Company?s advance toward a new U.S. SUI indication ENGLEWOOD, CO ? December 14, 2021 ? Viveve Medical, Inc. (NASDAQ: VIVE), a medical technology company focused on women's intimate health, announced today that it has completed enrollment in its pivot
December 14, 2021	8-K	Regulation FD Disclosure UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 14, 2021 VIVEVE MEDICAL, INC. (Exact name of registrant as specified in its charter) Delaware 1-11388 04-3153858 (State or other jurisdiction of incorporation) (Commission Fi
November 12, 2021	EX-99.1	Viveve Reports Third Quarter 2021 Financial Results and Provides Corporate Update Total revenue of $1.6M reported for Q3 Pivotal SUI PURSUIT trial enrollment nears completion – randomizations on-track for completion in Q4 Exhibit 99.1 Viveve Reports Third Quarter 2021 Financial Results and Provides Corporate Update Total revenue of $1.6M reported for Q3 Pivotal SUI PURSUIT trial enrollment nears completion ? randomizations on-track for completion in Q4 ENGLEWOOD, CO ? November 11, 2021 ? Viveve Medical, Inc. (NASDAQ: VIVE), a medical technology company focused on women's intimate health, today reported financial re
November 12, 2021	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 1-11388 VIVEVE M
November 12, 2021	8-K	Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 12, 2021 VIVEVE MEDICAL, INC. (Exact name of registrant as specified in its charter) Delaware 1-11388 04-3153858 (State or other jurisdiction of incorporation) (Commission Fi
October 28, 2021	EX-99.1	Viveve Announces Issuance of New Device and Methods Patent in U.S. Issuance further expands and strengthens Company’s intellectual property portfolio Exhibit 99.1 Viveve Announces Issuance of New Device and Methods Patent in U.S. Issuance further expands and strengthens Company?s intellectual property portfolio Englewood, CO ? October 28, 2021 ? Viveve Medical, Inc. (NASDAQ: VIVE), a medical technology company focused on women's intimate health, today announced that the United States Patent and Trademark Office (USPTO) recently issued U.S. Pate
October 28, 2021	8-K	Regulation FD Disclosure UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 28, 2021 VIVEVE MEDICAL, INC. (Exact name of registrant as specified in its charter) Delaware 1-11388 04-3153858 (State or other jurisdiction of incorporation) (Commission Fil
September 23, 2021	EX-99.1	Viveve Announces Issuance of New Method Patent for Stress Urinary Incontinence in Australia Patent strengthens and expands Viveve's intellectual property portfolio for the treatment of stress urinary incontinence Exhibit 99.1 Viveve Announces Issuance of New Method Patent for Stress Urinary Incontinence in Australia Patent strengthens and expands Viveve's intellectual property portfolio for the treatment of stress urinary incontinence ENGLEWOOD, CO ? September 23, 2021 - Viveve Medical, Inc. (NASDAQ: VIVE), a medical technology company focused on women's intimate health, today announced that the Australian
September 23, 2021	8-K	Regulation FD Disclosure UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 23, 2021 VIVEVE MEDICAL, INC. (Exact name of registrant as specified in its charter) Delaware 1-11388 04-3153858 (State or other jurisdiction of incorporation) (Commission F
September 7, 2021	EX-99.1	Viveve to Participate in H.C. Wainwright 23rd Annual Global Investment Conference Exhibit 99.1 Viveve to Participate in H.C. Wainwright 23rd Annual Global Investment Conference ENGLEWOOD, CO ? September 7, 2021 - Viveve Medical, Inc. (NASDAQ: VIVE), a medical technology company focused on women's intimate health, today announced that Scott Durbin, chief executive officer, will participate in the H.C. Wainwright 23rd Annual Global Investment Conference, September 13 ? 15, 2021.
September 7, 2021	8-K	Regulation FD Disclosure UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 7, 2021 VIVEVE MEDICAL, INC. (Exact name of registrant as specified in its charter) Delaware 1-11388 04-3153858 (State or other jurisdiction of incorporation) (Commission Fi
August 12, 2021	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 1-11388 VIVEVE MEDICA
August 12, 2021	EX-99.1	Viveve Reports Second Quarter 2021 Financial Results and Provides Corporate Update Total revenue of $1.7M reported for Q2 Reported sales of approximately 3,500 consumable treatment tips - a 42% unit increase quarter-over-quarter Pivotal SUI PURSUIT t Exhibit 99.1 Viveve Reports Second Quarter 2021 Financial Results and Provides Corporate Update Total revenue of $1.7M reported for Q2 Reported sales of approximately 3,500 consumable treatment tips - a 42% unit increase quarter-over-quarter Pivotal SUI PURSUIT trial enrollment on-track for completion in early Q4 Potential long-term reimbursement pathway established with new Category III CPT? code
August 12, 2021	8-K	Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 12, 2021 VIVEVE MEDICAL, INC. (Exact name of registrant as specified in its charter) Delaware 1-11388 04-3153858 (State or other jurisdiction of incorporation) (Commission File
August 3, 2021	8-K	Regulation FD Disclosure UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 3, 2021 VIVEVE MEDICAL, INC. (Exact name of registrant as specified in its charter) Delaware 1-11388 04-3153858 (State or other jurisdiction of incorporation) (Commission File
August 3, 2021	EX-99.1	Viveve Announces Continued Expansion of IP Portfolio with Issuance of Canadian Patent Exhibit 99.1 Viveve Announces Continued Expansion of IP Portfolio with Issuance of Canadian Patent Englewood, CO ? August 3, 2021 ? Viveve Medical, Inc. (NASDAQ: VIVE), a medical technology company focused on women?s intimate health, today announced that the Canadian Intellectual Property Office (CIPO) recently issued Canadian Patent No. 3028905 for Viveve?s dual-energy technology device and metho
July 7, 2021	EX-99.1	Viveve Announces New Category III CPT Code for its Stress Urinary Incontinence Procedure New code approved by American Medical Association and supported by key medical societies Long-term pathway for potential reimbursement now established for Compan Exhibit 99.1 Viveve Announces New Category III CPT Code for its Stress Urinary Incontinence Procedure New code approved by American Medical Association and supported by key medical societies Long-term pathway for potential reimbursement now established for Company?s dual-energy noninvasive treatment for urethral hypermobility to improve stress urinary incontinence in women Englewood, CO ? July 7,
July 7, 2021	8-K	Regulation FD Disclosure UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 7, 2021 VIVEVE MEDICAL, INC. (Exact name of registrant as specified in its charter) Delaware 1-11388 04-3153858 (State or other jurisdiction of incorporation) (Commission File Nu
July 6, 2021	8-K	Regulation FD Disclosure UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 6, 2021 VIVEVE MEDICAL, INC. (Exact name of registrant as specified in its charter) Delaware 1-11388 04-3153858 (State or other jurisdiction of incorporation) (Commission File Nu
July 6, 2021	EX-99.1	Viveve to Participate in Ladenburg Thalmann Healthcare Virtual Conference Exhibit 99.1 Viveve to Participate in Ladenburg Thalmann Healthcare Virtual Conference ENGLEWOOD, CO ? July 6, 2021 - Viveve Medical, Inc. (NASDAQ: VIVE), a medical technology company focused on women's intimate health, today announced that Scott Durbin, chief executive officer, will participate in the Ladenburg Thalmann Healthcare Conference, July 13 - 14, 2021. Mr. Durbin will deliver the Viveve
July 2, 2021	S-8	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 VIVEVE MEDICAL, INC. (Exact name of registrant as specified in its charter) As filed with the Securities and Exchange Commission on July 2, 2021 Registration No.
July 2, 2021	S-3	Power of Attorney (included on the signature pages to this registration statement) S-3 1 vive20210630s3.htm As filed with the Securities and Exchange Commission on July 2, 2021. Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-3 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 VIVEVE MEDICAL, INC. (Exact name of registrant as specified in its charter) Delaware 04-3153858 (State or other jurisdiction of incorporation or o
June 25, 2021	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 23, 2021 VIVEVE MEDICAL, INC. (Exact name of registrant as specified in its charter) Delaware 1-11388 04-3153858 (State or other jurisdiction of incorporation) (Commission File N
June 16, 2021	EX-3.1	Amendment to the Amended and Restated Bylaws. Exhibit 3.1 AMENDMENT TO AMENDED AND RESTATED BYLAWS OF VIVEVE MEDICAL, INC. The Amended and Restated Bylaws (the ?Bylaws?) of Viveve Medical, Inc., a Delaware corporation (the ?Company?) were amended by a resolution adopted by the board of directors of the Company on June 15, 2021 as follows: The first sentence of Article I, Section 5 of the Bylaws is hereby deleted in its entirety and replaced w
June 16, 2021	DEFA14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 DEFA14A 1 vive20210615defa14a.htm FORM DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the Appropriate Box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (a
June 16, 2021	8-K	Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 15, 2021 VIVEVE MEDICAL, INC. (Exact name of registrant as specified in its charter) Delaware 1-11388 04-3153858 (State or other jurisdiction of incorporation) (Commission File N
June 10, 2021	8-K	Regulation FD Disclosure UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 10, 2021 VIVEVE MEDICAL, INC. (Exact name of registrant as specified in its charter) Delaware 1-11388 04-3153858 (State or other jurisdiction of incorporation) (Commission File N
June 10, 2021	EX-99.1	Viveve Announces Issuance of New Device and Methods Patent in U.S. Issuance expands patent claims for Company’s dual-energy technology EX-99.1 2 ex256474.htm EXHIBIT 99.1 Exhibit 99.1 Viveve Announces Issuance of New Device and Methods Patent in U.S. Issuance expands patent claims for Company’s dual-energy technology Englewood, CO – June 10, 2021 – Viveve Medical, Inc. (NASDAQ: VIVE), a medical technology company focused on women's intimate health, today announced that the United States Patent and Trademark Office (USPTO) recentl
June 2, 2021	EX-99.1	VIVEVE ANNOUNCES ADJOURNMENT OF ANNUAL MEETING - Meeting scheduled to reconvene June 23, 2021 at 12:00 PM Eastern Time - Company encourages stockholders to cast their votes EX-99.1 2 ex254314.htm EXHIBIT 99.1 Exhibit 99.1 VIVEVE ANNOUNCES ADJOURNMENT OF ANNUAL MEETING - Meeting scheduled to reconvene June 23, 2021 at 12:00 PM Eastern Time - Company encourages stockholders to cast their votes ENGLEWOOD, CO – June 2, 2021 – Viveve Medical, Inc. (NASDAQ: VIVE), a medical technology company focused on women's intimate health, today announced that it has adjourned its 202
June 2, 2021	DEFA14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 2, 2021 VIVEVE MEDICAL, INC. UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 2, 2021 VIVEVE MEDICAL, INC. (Exact name of registrant as specified in its charter) Delaware 1-11388 04-3153858 (State or other jurisdiction of incorporation) (Commission File Nu
June 2, 2021	EX-99.1	Press Release issued by the Company on June 2, 2021, furnished herewith. EX-99.1 2 ex254314.htm EXHIBIT 99.1 Exhibit 99.1 VIVEVE ANNOUNCES ADJOURNMENT OF ANNUAL MEETING - Meeting scheduled to reconvene June 23, 2021 at 12:00 PM Eastern Time - Company encourages stockholders to cast their votes ENGLEWOOD, CO – June 2, 2021 – Viveve Medical, Inc. (NASDAQ: VIVE), a medical technology company focused on women's intimate health, today announced that it has adjourned its 202
June 2, 2021	8-K	Current Report UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 2, 2021 VIVEVE MEDICAL, INC. (Exact name of registrant as specified in its charter) Delaware 1-11388 04-3153858 (State or other jurisdiction of incorporation) (Commission File Nu
May 13, 2021	8-K	Results of Operations and Financial Condition 8-K 1 vive202105138k.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 13, 2021 VIVEVE MEDICAL, INC. (Exact name of registrant as specified in its charter) Delaware 1-11388 04-3153858 (State or other jurisdiction of
May 13, 2021	EX-99.1	Viveve Reports First Quarter 2021 Financial Results and Provides Corporate Update Pivotal SUI PURSUIT trial enrollment underway and accelerating Total revenue of $1.5M for Q1 including sale of 2,450 consumable treatment tips Strengthened patent portf Exhibit 99.1 Viveve Reports First Quarter 2021 Financial Results and Provides Corporate Update Pivotal SUI PURSUIT trial enrollment underway and accelerating Total revenue of $1.5M for Q1 including sale of 2,450 consumable treatment tips Strengthened patent portfolio in key Asia Pacific markets ENGLEWOOD, CO ? May 13, 2021 ? Viveve Medical, Inc. (NASDAQ: VIVE), a medical technology company focused
May 13, 2021	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 1-11388 VIVEVE MEDIC
May 11, 2021	EX-99.1	Press Release issued by the Company on May 11, 2021, furnished herewith. Exhibit 99.1 VIVEVE ANNOUNCES ADJOURNMENT OF ANNUAL MEETING - Meeting scheduled to reconvene June 2, 2021 at 12:00 PM Eastern Time - Company encourages stockholders to cast their votes ENGLEWOOD, CO ? May 11, 2021 ? Viveve Medical, Inc. (NASDAQ: VIVE), a medical technology company focused on women's intimate health, today announced that it has adjourned its 2021 Annual Meeting of Stockholders due
May 11, 2021	EX-99.1	VIVEVE ANNOUNCES ADJOURNMENT OF ANNUAL MEETING - Meeting scheduled to reconvene June 2, 2021 at 12:00 PM Eastern Time - Company encourages stockholders to cast their votes Exhibit 99.1 VIVEVE ANNOUNCES ADJOURNMENT OF ANNUAL MEETING - Meeting scheduled to reconvene June 2, 2021 at 12:00 PM Eastern Time - Company encourages stockholders to cast their votes ENGLEWOOD, CO ? May 11, 2021 ? Viveve Medical, Inc. (NASDAQ: VIVE), a medical technology company focused on women's intimate health, today announced that it has adjourned its 2021 Annual Meeting of Stockholders due
May 11, 2021	DEFA14A	- FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 11, 2021 VIVEVE MEDICAL, INC. (Exact name of registrant as specified in its charter) Delaware 1-11388 04-3153858 (State or other jurisdiction of incorporation) (Commission File Nu
May 11, 2021	8-K	Current Report UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 11, 2021 VIVEVE MEDICAL, INC. (Exact name of registrant as specified in its charter) Delaware 1-11388 04-3153858 (State or other jurisdiction of incorporation) (Commission File Nu
April 20, 2021	424B3	3,500,000 Shares Common Stock Filed Pursuant to Rule 424(b)(3) Registration No. 333-254926 3,500,000 Shares Common Stock This prospectus relates to the offer and sale of up to 3,500,000 shares of common stock, par value $0.0001 per share, of Viveve Medical, Inc., a Delaware corporation, by Lincoln Park Capital Fund, LLC, or Lincoln Park or the Selling Stockholder. The shares of common stock being offered by the Selling Stockho
April 15, 2021	CORRESP	Viveve Medical, Inc. 345 Inverness Drive South Building B, Suite 250 Englewood, CO 80112 Viveve Medical, Inc. 345 Inverness Drive South Building B, Suite 250 Englewood, CO 80112 VIA EDGAR April 15, 2021 United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, DC 20549 Attention: Tom Jones Tim Buchmiller Re: Viveve Medical, Inc. Acceleration Request for Registration Statement on Form S-1 File No. 333- 254926 Dear Messrs. Jones and
April 1, 2021	8-K	Regulation FD Disclosure UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 1, 2021 VIVEVE MEDICAL, INC. (Exact name of registrant as specified in its charter) Delaware 1-11388 04-3153858 (State or other jurisdiction of incorporation) (Commission File N
April 1, 2021	EX-99.1	Viveve Announces Expansion of IP Portfolio with Patent Issuance in Taiwan EX-99.1 2 ex238656.htm EXHIBIT 99.1 Exhibit 99.1 Viveve Announces Expansion of IP Portfolio with Patent Issuance in Taiwan Englewood, CO – April 1, 2021 – Viveve Medical, Inc. (NASDAQ: VIVE), a medical technology company focused on women's intimate health, today announced that the Taiwan Intellectual Property Office (TIPO) recently issued Taiwan Patent No. 1720358 for Viveve’s dual-energy technolo
March 31, 2021	8-K	Entry into a Material Definitive Agreement UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 31, 2021 VIVEVE MEDICAL, INC. (Exact name of registrant as specified in its charter) Delaware 1-11388 04-3153858 (State or other jurisdiction of incorporation) (Commission File
March 31, 2021	S-8	- FORM S-8 As filed with the Securities and Exchange Commission on March 31, 2021 Registration No.
March 31, 2021	S-1	Registration Statement - FORM S-1 As filed with the Securities and Exchange Commission on March 31, 2021 Registration No.
March 31, 2021	DEF 14A	Schedule 14A DEF 14A 1 vive20210329def14a.htm FORM DEF 14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted
March 31, 2021	EX-10.1	First Amendment to the Purchase Agreement between the Registrant and Lincoln Park Capital, LLC, dated March 31, 2021 (37) EX-10.1 2 ex238431.htm EXHIBIT 10.1 Exhibit 10.1 FIRST AMENDMENT TO PURCHASE AGREEMENT THIS FIRST AMENDMENT TO PURCHASE AGREEMENT (this “First Amendment”), dated as of March 31, 2021, by and between VIVEVE MEDICAL, INC., a Delaware corporation (the “Company”), and LINCOLN PARK CAPITAL FUND, LLC, an Illinois limited liability company (the “Investor”). WHEREAS, the Company and the Investor entered i
March 18, 2021	EX-10.27	Amendment No. 1 to Sublease Agreement, effective as of March 15, 2021, by and between the Registrant and Ingredion Incorporated. (36) Exhibit 10.27 FIRST AMENDMENT TO SUBLEASE AGREEMENT THIS FIRST AMENDMENT TO SUBLEASE AGREEMENT (hereinafter referred to as this ?Amendment?) is made effective as of March 15, 2021 (the ?Effective Date?) by and between Ingredion Incorporated, a Delaware corporation (?Sublandord?), and Viveve Medical, Inc., a Delaware corporation (?Subtenant?). WITNESSETH: WHEREAS, Sublandord and Subtenant are party
March 18, 2021	8-K	Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 18, 2021 VIVEVE MEDICAL, INC. (Exact name of registrant as specified in its charter) Delaware 1-11388 04-3153858 (State or other jurisdiction of incorporation) (Commission File
March 18, 2021	EX-4.20	Description of Securities* Exhibit 4.20 DESCRIPTION OF THE REGISTRANT?S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 As of December 31, 2020 Viveve Medical, Inc. (?Viveve?) has one class of securities registered under Section 12 of the Securities Exchange Act of 1934, as amended (the ?Exchange Act?): common stock, par value $0.0001 per share (the ?common stock?). DESCRIPTION OF COMMON
March 18, 2021	EX-99.1	Viveve Reports Full Year 2020 Financial Results and Provides Corporate Update Company continuing to advance its U.S. pivotal PURSUIT trial in stress urinary incontinence Conference call to be hosted by Company at 5:00 PM ET today Exhibit 99.1 Viveve Reports Full Year 2020 Financial Results and Provides Corporate Update Company continuing to advance its U.S. pivotal PURSUIT trial in stress urinary incontinence Conference call to be hosted by Company at 5:00 PM ET today Englewood, CO – March 18, 2021 – Viveve Medical, Inc. (NASDAQ: VIVE), a medical technology company focused on women's intimate health, today reported financi
March 18, 2021	10-K	Annual Report - FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K (Mark One) ? ANNUAL REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 or ? TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from .
February 18, 2021	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 18, 2021 VIVEVE MEDICAL, INC. (Exact name of registrant as specified in its charter) Delaware 1-11388 04-3153858 (State or other jurisdiction of incorporation) (Commission Fi
February 18, 2021	EX-99.1	Viveve Announces Preliminary Topline Financial Results for Fourth Quarter 2020 - Q4 revenue growth, reduced operating expenses and successful closing of public offering in January position Company with capital resources through end of 2022 - Company Exhibit 99.1 Viveve Announces Preliminary Topline Financial Results for Fourth Quarter 2020 - Q4 revenue growth, reduced operating expenses and successful closing of public offering in January position Company with capital resources through end of 2022 - Company to host year-end conference call on March 18, 2021 at 5:00 PM ET Englewood, CO – February 18, 2021 – Viveve Medical, Inc. (NASDAQ: VIVE),
February 16, 2021	SC 13G/A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* Viveve Medical, Inc. UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No.
February 11, 2021	SC 13G/A	Viveve Medical, Inc. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* Viveve Medical, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 92852W501 (CUSIP Number) December 31, 2020 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant
February 2, 2021	EX-99.1	Viveve Announces Expansion of IP Portfolio with Issuance of S. Korean Patent EX-99.1 2 ex223738.htm EXHIBIT 99.1 Exhibit 99.1 Viveve Announces Expansion of IP Portfolio with Issuance of S. Korean Patent Englewood, CO – February 2, 2021 – Viveve Medical, Inc. (NASDAQ: VIVE), a medical technology company focused on women's intimate health, today announced that the Korean Intellectual Property Office (KIPO) recently issued Korean Patent No. 10-2197234 titled, Vaginal Remodeli
February 2, 2021	8-K	Financial Statements and Exhibits - FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 2, 2021 VIVEVE MEDICAL, INC. (Exact name of registrant as specified in its charter) Delaware 1-11388 04-3153858 (State or other jurisdiction of incorporation) (Commission Fil
January 21, 2021	EX-99.1	Viveve Announces Initiation of Pivotal U.S. PURSUIT Trial in Stress Urinary Incontinence - New study design is more highly powered with improved patient selection criteria to better assess the primary efficacy endpoint - Positive results could suppor Exhibit 99.1 Viveve Announces Initiation of Pivotal U.S. PURSUIT Trial in Stress Urinary Incontinence - New study design is more highly powered with improved patient selection criteria to better assess the primary efficacy endpoint - Positive results could support a marketing application for new U.S. stress urinary incontinence indication ENGLEWOOD, CO – January 21, 2021 – Viveve Medical, Inc. (NA
January 21, 2021	8-K	Financial Statements and Exhibits - FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 21, 2021 VIVEVE MEDICAL, INC. (Exact name of registrant as specified in its charter) Delaware 1-11388 04-3153858 (State or other jurisdiction of incorporation) (Commission Fil
January 19, 2021	EX-99.1	VIVEVE ANNOUNCES CLOSING OF AN UPSIZED $27.6 MILLION UNDERWRITTEN PUBLIC OFFERING AND EXERCISE OF OVER-ALLOTMENT OPTION Exhibit 99.1 VIVEVE ANNOUNCES CLOSING OF AN UPSIZED $27.6 MILLION UNDERWRITTEN PUBLIC OFFERING AND EXERCISE OF OVER-ALLOTMENT OPTION ENGLEWOOD, CO / ACCESSWIRE / January 19, 2021 / Viveve Medical, Inc. ("Viveve") (NASDAQ: VIVE), a medical technology company focused on women's intimate health, today announced the closing of an upsized underwritten public offering of units for gross proceeds of appr
January 19, 2021	SC 13G	Viveve Medical, Inc. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Viveve Medical, Inc. (Name of Issuer) Common Stock, par value $0.0001 (Title of Class of Securities) 92852W501 (CUSIP Number) January 14, 2021 (Date of event which requires filing of this statement) Check the appropriate box to designate the rule pursuant to which this
January 19, 2021	EX-3.1	Form of Certificate of Designation of Preferences, Rights and Limitations of Series C Preferred Stock (35) Exhibit 3.1 VIVEVE MEDICAL, INC. CERTIFICATE OF DESIGNATION OF PREFERENCES, RIGHTS AND LIMITATIONS OF SERIES C CONVERTIBLE PREFERRED STOCK PURSUANT TO SECTION 151 OF THE DELAWARE GENERAL CORPORATION LAW The undersigned, Scott Durbin and Heidi Mayon, do hereby certify that: 1. They are the Chief Executive Officer and Secretary, respectively, of Viveve Medical, Inc., a Delaware corporation (the “Cor
January 19, 2021	8-K	Regulation FD Disclosure, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Entry into a Material Definitive Agreement, Financial Statements and Exhibits - FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 14, 2021 VIVEVE MEDICAL, INC. (Exact name of registrant as specified in its charter) Delaware 1-11388 04-3153858 (State or other jurisdiction of incorporation) (Commission Fil
January 19, 2021	SC 13G	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* VIVEVE MEDICAL, INC. (Name of Issuer) COMMON STOCK, $0.0001 PAR VALUE (Title of Class of Securities) 9285 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* VIVEVE MEDICAL, INC. (Name of Issuer) COMMON STOCK, $0.0001 PAR VALUE (Title of Class of Securities) 92852W303 (CUSIP Number) January 14, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant
January 14, 2021	424B4	Per Class A Unit(1) PROSPECTUS Filed Pursuant to Rule 424(b)(4) Registration No. 333-251517 4,607,940 Class A Units consisting of 4,607,940 shares of common stock and warrants to purchase up to 4,607,940 shares of common stock and 2,450,880 Class B Units consisting of 2,450,880 shares of Series C Preferred Stock and warrants to purchase up to 2,450,880 shares of common stock (and 9,509,700 shares of common stock unde
January 13, 2021	CORRESP	- January 13, 2021 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance 100 F Street N.
January 13, 2021	S-1/A	- FORM S-1/A As filed with the Securities and Exchange Commission on January 13, 2021 Registration No.
January 13, 2021	CORRESP	- Viveve Medical, Inc. 345 Inverness Drive South Building B, Suite 250 Englewood, CO 80112 VIA EDGAR January 13, 2021 United States Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, N.E. Washington, DC 20549 Attention: Alan Campbell Re: Viveve Medical, Inc. Acceleration Request for Registration Statement on Form S-1 Filed December 18, 2020 File
January 13, 2021	S-1MEF	- FORM S-1MEF As filed with the Securities and Exchange Commission on January 13, 2021. Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 VIVEVE MEDICAL, INC. (Exact name of registrant as specified in its charter) Delaware 3841 04-3153858 (State or other jurisdiction of (Primary Standard Industrial (I.R.
January 12, 2021	EX-1.1	Form of Underwriting Agreement* Exhibit 1.1 UNDERWRITING AGREEMENT between VIVEVE MEDICAL, INC. and A.G.P./ALLIANCE GLOBAL PARTNERS, as Representative of the Several Underwriters Viveve Medical, Inc. UNDERWRITING AGREEMENT New York, New York January , 2021 A.G.P./Alliance Global Partners As Representative of the several Underwriters named on Schedule 1 attached hereto 590 Madison Avenue, 28th Floor New York, New York 10022 Ladie
January 12, 2021	EX-4.16	Form of Common Stock Purchase Warrant for the 2021 Warrants (35) Exhibit 4.16 COMMON STOCK PURCHASE WARRANT VIVEVE medical, INC. Warrant Shares: Original Issue Date: , 2021 THIS COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date hereof (the “Initial Exercise
January 12, 2021	S-1/A	Form of Warrant Agent Agreement by and between VStock Transfer LLC and the Registrant, effective January 2021 (35) As filed with the Securities and Exchange Commission on January 12, 2021 Registration No.
January 12, 2021	EX-4.18	Form of Warrant Agent Agreement by and between VStock Transfer LLC and the Registrant, effective January 2021 (35) EX-4.18 4 ex220561.htm EXHIBIT 4.18 Exhibit 4.18 WARRANT AGENT AGREEMENT This Warrant Agent Agreement made as of [], 2021, is between Viveve Medical, Inc., a Delaware corporation, with offices at 345 Inverness Drive South, Building B, Suite 250, Englewood, CO 80112 (the “Company”), and VStock Transfer, LLC, with offices at 18 Lafayette Place, Woodmere, New York (the “Warrant Agent”). WHEREAS, the
January 4, 2021	FWP	FWP
December 31, 2020	EX-1.1	Form of Underwriting Agreement* Exhibit 1.1 UNDERWRITING AGREEMENT between VIVEVE MEDICAL, INC. and A.G.P./ALLIANCE GLOBAL PARTNERS, as Representative of the Several Underwriters Viveve Medical, Inc. UNDERWRITING AGREEMENT New York, New York , 2021 A.G.P./Alliance Global Partners As Representative of the several Underwriters named on Schedule 1 attached hereto 590 Madison Avenue, 28th Floor New York, New York 10022 Ladies and Ge
December 31, 2020	S-1/A	- FORM S-1/A As filed with the Securities and Exchange Commission on December 31, 2020 Registration No.
December 31, 2020	EX-3.8	Form of Certificate of Designation of Preferences, Rights and Limitations of Series C Preferred Stock** Exhibit 3.8 VIVEVE MEDICAL, INC. CERTIFICATE OF DESIGNATION OF PREFERENCES, RIGHTS AND LIMITATIONS OF SERIES C CONVERTIBLE PREFERRED STOCK PURSUANT TO SECTION 151 OF THE DELAWARE GENERAL CORPORATION LAW The undersigned, and , do hereby certify that: 1. They are the Chief Executive Officer and Secretary, respectively, of Viveve Medical, Inc., a Delaware corporation (the “Corporation”). 2. The Corpo
December 18, 2020	S-1	Power of Attorney** As filed with the Securities and Exchange Commission on December 18, 2020 Registration No.
December 17, 2020	EX-3.1	Certificate of Elimination of Series A Preferred Stock (34) Exhibit 3.1 CERTIFICATE OF ELIMINATION OF SERIES A CONVERTIBLE PREFERRED STOCK, A SERIES OF PREFERRED STOCK OF VIVEVE MEDICAL, INC. (Pursuant to Section 151(g) of the Delaware General Corporation Law) VIVEVE MEDICAL, INC., a corporation organized and existing under the laws of the State of Delaware (the “Corporation”), does hereby certify that the following resolutions respecting Series A Converti
December 17, 2020	EX-99.1	Viveve Regains Compliance with NASDAQ Continued Listing Rules Exhibit 99.1 Viveve Regains Compliance with NASDAQ Continued Listing Rules ENGLEWOOD, CO – December 17, 2020 – Viveve Medical, Inc. (NASDAQ: VIVE), a medical technology company focused on women’s intimate health, announced today that it received notice from The NASDAQ Stock Market LLC (NASDAQ) on December 16, 2020 that the Company has regained compliance with the $1.00 minimum bid price requiremen
December 17, 2020	8-K	Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Material Modification to Rights of Security Holders, Financial Statements and Exhibits - FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 16, 2020 VIVEVE MEDICAL, INC. (Exact name of registrant as specified in its charter) Delaware 1-11388 04-3153858 (State or other jurisdiction of incorporation) (Commission Fi
December 10, 2020	8-K	Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 10, 2020 VIVEVE MEDICAL, INC. (Exact name of registrant as specified in its charter) Delaware 1-11388 04-3153858 (State or other jurisdiction of incorporation) (Commission Fi
December 10, 2020	EX-99.1	Viveve Announces FDA Approval of Proposed Amendments to Pivotal U.S. PURSUIT Trial Protocol - Viveve authorized to increase trial size and introduce new patient selection criteria designed to improve study’s power and data to support assessment of pr Exhibit 99.1 Viveve Announces FDA Approval of Proposed Amendments to Pivotal U.S. PURSUIT Trial Protocol - Viveve authorized to increase trial size and introduce new patient selection criteria designed to improve study?s power and data to support assessment of primary efficacy endpoint - Near-term launch planned for pivotal U.S. PURSUIT trial ENGLEWOOD, CO ? December 10, 2020 ? Viveve Medical, Inc
December 3, 2020	8-K	Financial Statements and Exhibits - FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 3, 2020 VIVEVE MEDICAL, INC. (Exact name of registrant as specified in its charter) Delaware 1-11388 04-3153858 (State or other jurisdiction of incorporation) (Commission Fil
December 3, 2020	EX-99.1	Viveve Announces FDA 510K Approval to Expand Manufacturing of Treatment Tips Exhibit 99.1 Viveve Announces FDA 510K Approval to Expand Manufacturing of Treatment Tips - Approval strengthens supply chain and reduces manufacturing costs for consumable component used with Viveve’s Cryogen-cooled Monopolar Radiofrequency technology ENGLEWOOD, CO – December 3, 2020 – Viveve Medical, Inc. (NASDAQ: VIVE), a medical technology company focused on women's intimate health, today anno
December 1, 2020	EX-3.1	Certificate of Amendment to the Amended and Restated Certificate of Incorporation filed November 30, 2020. Exhibit 3.1 CERTIFICATE OF AMENDMENT TO THE AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF VIVEVE MEDICAL, INC. Viveve Medical, Inc. (the “Corporation”), a corporation organized and existing under the laws of the State of Delaware, hereby certifies as follows: FIRST: That the name of the Corporation is Viveve Medical, Inc. The date of the filing of its original Certificate of Incorporation w
December 1, 2020	8-K	Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Material Modification to Rights of Security Holders, Financial Statements and Exhibits - FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 30, 2020 VIVEVE MEDICAL, INC. (Exact name of registrant as specified in its charter) Delaware 1-11388 04-3153858 (State or other jurisdiction of incorporation) (Commission Fi
November 12, 2020	10-Q	Quarterly Report - FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 1-11388 VIVEVE M
November 12, 2020	EX-99.1	Viveve Reports Third Quarter 2020 Financial Results and Provides Corporate Update Exhibit 99.1 Viveve Reports Third Quarter 2020 Financial Results and Provides Corporate Update - Company shifts strategic focus to stress urinary incontinence - Positive feasibility study and preclinical results advance clinical development program targeting treatment of stress urinary incontinence - Near-term launch planned for U.S. pivotal PURSUIT trial - Company to host conference call at 5:00
November 12, 2020	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 12, 2020 VIVEVE MEDICAL, INC. (Exact name of registrant as specified in its charter) Delaware 1-11388 04-3153858 (State or other jurisdiction of incorporation) (Commission Fi
November 10, 2020	8-K	Financial Statements and Exhibits - FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 10, 2020 VIVEVE MEDICAL, INC. (Exact name of registrant as specified in its charter) Delaware 1-11388 04-3153858 (State or other jurisdiction of incorporation) (Commission Fi
November 10, 2020	EX-99.1	Viveve to Participate in Alliance Group Partners Virtual Healthcare Symposium Exhibit 99.1 Viveve to Participate in Alliance Group Partners Virtual Healthcare Symposium ENGLEWOOD, CO – November 10, 2020 - Viveve Medical, Inc. (NASDAQ: VIVE), a medical technology company focused on women's intimate health, today announced that Scott Durbin, chief executive officer, will participate in the Alliance Group Partners Virtual Healthcare Symposium on November 19, 2020. Mr. Durbin w
October 30, 2020	8-K	Regulation FD Disclosure, Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits - FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 28, 2020 VIVEVE MEDICAL, INC. (Exact name of registrant as specified in its charter) Delaware 1-11388 04-3153858 (State or other jurisdiction of incorporation) (Commission Fil
October 30, 2020	EX-99.1	Viveve Appoints New Independent Board Director Exhibit 99.1 Viveve Appoints New Independent Board Director ENGLEWOOD, CO – October 30, 2020 - Viveve Medical, Inc. (NASDAQ: VIVE), a medical technology company focused on women’s intimate health, today announced that Sharon Collins Presnell, Ph.D. has joined the Viveve board of directors and its audit committee, effective October 28, 2020. The appointment of Dr. Presnell brings the company in com
October 27, 2020	8-K	Financial Statements and Exhibits - FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 27, 2020 VIVEVE MEDICAL, INC. (Exact name of registrant as specified in its charter) Delaware 1-11388 04-3153858 (State or other jurisdiction of incorporation) (Commission Fil
October 27, 2020	EX-99.1	Viveve Launches New Clinical Advisory Board in Urinary Incontinence Preeminent urology and urogynecology experts to help guide and advance the company’s pivotal U.S. PURSUIT trial in Stress Urinary Incontinence Exhibit 99.1 Viveve Launches New Clinical Advisory Board in Urinary Incontinence Preeminent urology and urogynecology experts to help guide and advance the company’s pivotal U.S. PURSUIT trial in Stress Urinary Incontinence ENGLEWOOD, CO – October 27, 2020 - Viveve Medical, Inc. (NASDAQ: VIVE), a medical technology company focused on women’s intimate health, today announced that it has formed a cl
September 22, 2020	EX-99.1	Viveve Announces Issuance of Novel U.S. Method Patent for Stress Urinary Incontinence New patent strengthens and expands Viveve’s intellectual property portfolio for the treatment of stress urinary incontinence Exhibit 99.1 Viveve Announces Issuance of Novel U.S. Method Patent for Stress Urinary Incontinence New patent strengthens and expands Viveve’s intellectual property portfolio for the treatment of stress urinary incontinence ENGLEWOOD, CO – September 22, 2020 - Viveve Medical, Inc. (NASDAQ: VIVE), a medical technology company focused on women’s intimate health, today announced that the United State
September 22, 2020	8-K	Financial Statements and Exhibits - FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 22, 2020 VIVEVE MEDICAL, INC. (Exact name of registrant as specified in its charter) Delaware 1-11388 04-3153858 (State or other jurisdiction of incorporation) (Commission F
September 3, 2020	EX-99.1	Viveve to Present at H.C. Wainwright 22nd Annual Global Investment Conference Exhibit 99.1 Viveve to Present at H.C. Wainwright 22nd Annual Global Investment Conference ENGLEWOOD, CO – September 3, 2020 - Viveve Medical, Inc. (NASDAQ: VIVE), a medical technology company focused on women's intimate health, today announced that Scott Durbin, chief executive officer, will present at the H.C. Wainwright 22nd Annual Global Investment Conference. Mr. Durbin will also meet with me
September 3, 2020	8-K	Financial Statements and Exhibits - FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 3, 2020 VIVEVE MEDICAL, INC. (Exact name of registrant as specified in its charter) Delaware 1-11388 04-3153858 (State or other jurisdiction of incorporation) (Commission Fi
September 1, 2020	8-K	Financial Statements and Exhibits - FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 1, 2020 VIVEVE MEDICAL, INC. (Exact name of registrant as specified in its charter) Delaware 1-11388 04-3153858 (State or other jurisdiction of incorporation) (Commission Fi
September 1, 2020	EX-99.1	Viveve Announces Exercise of Warrants for $3.6 Million Exhibit 99.1 Viveve Announces Exercise of Warrants for $3.6 Million - Proceeds to support upcoming pivotal PURSUIT Trial in U.S. following recent announcement of positive results from SUI feasibility and preclinical studies ENGLEWOOD, CO – September 1, 2020 – Viveve Medical, Inc. (NASDAQ: VIVE), a medical technology company focused on women’s intimate health, today announced it has received $3.6 m
August 25, 2020	8-K	Financial Statements and Exhibits - FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 25, 2020 VIVEVE MEDICAL, INC. (Exact name of registrant as specified in its charter) Delaware 1-11388 04-3153858 (State or other jurisdiction of incorporation) (Commission File
August 25, 2020	EX-99.1	Viveve Announces Positive Primary Efficacy Data from its SUI Feasibility Study and Positive Preclinical Outcomes that Support the Company’s New Sham Tip for Pivotal PURSUIT Trial Exhibit 99.1 Viveve Announces Positive Primary Efficacy Data from its SUI Feasibility Study and Positive Preclinical Outcomes that Support the Company’s New Sham Tip for Pivotal PURSUIT Trial - Achievement of primary efficacy endpoint in 3-arm SUI feasibility study demonstrates significant separation between CMRF treatment arm and inert sham arm - Positive in-vivo preclinical study validates new i
August 13, 2020	EX-99.1	Viveve Reports Second Quarter 2020 Financial Results and Provides Corporate Update Exhibit 99.1 Viveve Reports Second Quarter 2020 Financial Results and Provides Corporate Update - Advanced critical SUI feasibility study for late summer readout - Achieved FDA clearance to conduct pivotal SUI PURSUIT Trial - Company to host conference call at 5:00 PM ET today ENGLEWOOD, CO – August 13, 2020 – Viveve Medical, Inc. (NASDAQ: VIVE), a medical technology company focused on women's int
August 13, 2020	10-Q	Quarterly Report - FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 1-11388 VIVEVE MEDICA
August 13, 2020	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 13, 2020 VIVEVE MEDICAL, INC. (Exact name of registrant as specified in its charter) Delaware 1-11388 04-3153858 (State or other jurisdiction of incorporation) (Commission File
July 23, 2020	8-K	Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 22, 2020 VIVEVE MEDICAL, INC. (Exact name of registrant as specified in its charter) Delaware 1-11388 04-3153858 (State or other jurisdiction of incorporation) (Commission File N
July 14, 2020	EX-99.1	Viveve Announces Clearance of Viveve 2.0 System in Thailand Regulatory clearance expands availability of next-generation CMRF system in key Southeast Asia market Exhibit 99.1 Viveve Announces Clearance of Viveve 2.0 System in Thailand Regulatory clearance expands availability of next-generation CMRF system in key Southeast Asia market ENGLEWOOD, CO – July 14, 2020 – Viveve Medical, Inc. (NASDAQ: VIVE), a medical technology company focused on women’s intimate health, today announced it has received regulatory clearance from the Thai Food and Drug Administra
July 14, 2020	8-K	Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 14, 2020 VIVEVE MEDICAL, INC. (Exact name of registrant as specified in its charter) Delaware 1-11388 04-3153858 (State or other jurisdiction of incorporation) (Commission File N
July 7, 2020	8-K	Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 7, 2020 VIVEVE MEDICAL, INC. (Exact name of registrant as specified in its charter) Delaware 1-11388 04-3153858 (State or other jurisdiction of incorporation) (Commission File Nu
July 7, 2020	424B3	5,000,000 Shares Common Stock Filed Pursuant to Rule 424(b)(3) Registration Nos. 333-239280 5,000,000 Shares Common Stock This prospectus relates to the offer and sale of up to 5,000,000 shares of common stock, par value $0.0001 per share, of Viveve Medical, Inc., a Delaware corporation, by Lincoln Park Capital Fund, LLC, or Lincoln Park or the Selling Stockholder. The shares of common stock being offered by the Selling Stockh
July 7, 2020	424B3	5,063,374 Shares Common Stock Filed Pursuant to Rule 424(b)(3) Registration Nos. 333-239279 5,063,374 Shares Common Stock The selling stockholders named in this prospectus may offer and sell from time to time up to an aggregate of 5,063,374 shares of common stock issued or issuable upon exercise of warrants. We will not receive any proceeds from the sale by the selling stockholders of their shares of common stock other than th
July 7, 2020	EX-99.1	Viveve Announces FDA Approval to Conduct PURSUIT Trial for Improvement of Stress Urinary Incontinence Initiation of pivotal PURSUIT trial is targeted for Q4 2020 following pending results from Company's SUI feasibility study, which is evaluating a ne Exhibit 99.1 Viveve Announces FDA Approval to Conduct PURSUIT Trial for Improvement of Stress Urinary Incontinence Initiation of pivotal PURSUIT trial is targeted for Q4 2020 following pending results from Company's SUI feasibility study, which is evaluating a new sham treatment tip PURSUIT clearance and pending results from the SUI feasibility study are significant milestones in Company's pursuit
July 1, 2020	CORRESP	- Viveve Medical, Inc. 345 Inverness Drive South Building B, Suite 250 Englewood, CO 80112 VIA EDGAR July 1, 2020 United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, DC 20549 Attention: Tom Jones Tim Buchmiller Re: Viveve Medical, Inc. Acceleration Request for Registration Statement on Form S-1 File No. 333-239280 Dear Messrs. Jones and Buc
July 1, 2020	CORRESP	- Viveve Medical, Inc. 345 Inverness Drive South Building B, Suite 250 Englewood, CO 80112 VIA EDGAR July 1, 2020 United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, DC 20549 Attention: Tom Jones Tim Buchmiller Re: Viveve Medical, Inc. Acceleration Request for Registration Statement on Form S-1 File No. 333-239279 Dear Messrs. Jones and Buc
June 30, 2020	EX-99.1	Press Release issued on June 29, 2020 Exhibit 99.1 VIVEVE MEDICAL ANNOUNCES ADJOURNMENT OF ANNUAL MEETING - Meeting scheduled to reconvene July 22, 2020 at 10:30 AM Eastern Time ENGLEWOOD, CO – June 29, 2020 – Viveve Medical, Inc. (NASDAQ: VIVE), a medical technology company focused on women's intimate health, today announced that it has adjourned its 2020 Annual Meeting of Stockholders in order to permit stockholders additional time
June 30, 2020	10-K/A	Annual Report - FORM 10-K/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 AMENDMENT NO.
June 30, 2020	DEFA14A	- FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 29, 2020 VIVEVE MEDICAL, INC. (Exact name of registrant as specified in its charter) Delaware 1-11388 04-3153858 (State or other jurisdiction of incorporation) (Commission File N
June 30, 2020	EX-99.1	VIVEVE MEDICAL ANNOUNCES ADJOURNMENT OF ANNUAL MEETING Exhibit 99.1 VIVEVE MEDICAL ANNOUNCES ADJOURNMENT OF ANNUAL MEETING - Meeting scheduled to reconvene July 22, 2020 at 10:30 AM Eastern Time ENGLEWOOD, CO – June 29, 2020 – Viveve Medical, Inc. (NASDAQ: VIVE), a medical technology company focused on women's intimate health, today announced that it has adjourned its 2020 Annual Meeting of Stockholders in order to permit stockholders additional time
June 30, 2020	8-K	Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 29, 2020 VIVEVE MEDICAL, INC. (Exact name of registrant as specified in its charter) Delaware 1-11388 04-3153858 (State or other jurisdiction of incorporation) (Commission File N
June 18, 2020	RW	- FORM RW Goodwin Procter LLP 601 Marshall Street Redwood City, CA 94063 goodwinlaw.com +1 650 752 3100 June 18, 2020 Ms. Laura Crotty Ms. Mary Beth Breslin Office of Life Sciences Division of Corporation Finance Securities and Exchange Commission 100 F Street, N.E. Washington, D.C. 20549 Re: Viveve Medical, Inc. Registration Statement on Form S-3 Filed May 14, 2020 File No. 333-238263 Dear Misses Crotty an
June 18, 2020	10-K/A	Annual Report - FORM 10-K/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 AMENDMENT NO.
June 18, 2020	S-1	Registration Statement - FORM S-1 As filed with the Securities and Exchange Commission on June 18, 2020 Registration No.
June 18, 2020	S-1	Registration Statement - FORM S-1 As filed with the Securities and Exchange Commission on June 18, 2020 Registration No.
June 18, 2020	CORRESP	- Goodwin Procter LLP 601 Marshall Street Redwood City, CA 94063 goodwinlaw.com +1 650 752 3100 June 18, 2020 Mr. David Burton Ms. Lynn Dicker Office of Life Sciences Division of Corporation Finance Securities and Exchange Commission 100 F Street, N.E. Washington, D.C. 20549 Re: Viveve Medical, Inc. Form 10-K for the Fiscal Year Ended December 31, 2019 Filed March 19, 2020 File No. 001-11388 Dear Mr
June 10, 2020	8-K	Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 8, 2020 VIVEVE MEDICAL, INC. (Exact name of registrant as specified in its charter) Delaware 1-11388 04-3153858 (State or other jurisdiction of incorporation) (Commission File Nu
June 10, 2020	EX-10.1	Purchase Agreement between the Registrant and Lincoln Park Capital, LLC dated June 8, 2020 (31) Exhibit 10.1 PURCHASE AGREEMENT THIS PURCHASE AGREEMENT (the “Agreement”), dated as of June 8, 2020, by and between VIVEVE MEDICAL, INC., a Delaware corporation (the “Company”), and LINCOLN PARK CAPITAL FUND, LLC, an Illinois limited liability company (the “Investor”). WHEREAS: Subject to the terms and conditions set forth in this Agreement, the Company wishes to sell to the Investor, and the Inve
June 10, 2020	EX-10.2	Registration Rights Agreement between the Registrant and Lincoln Park Capital, LLC dated June 8, 2020 (31) Exhibit 10.2 REGISTRATION RIGHTS AGREEMENT THIS REGISTRATION RIGHTS AGREEMENT (this “Agreement”), dated as of June 8, 2020, is entered into by and between VIVEVE MEDICAL, INC., a Delaware corporation (the “Company”), and LINCOLN PARK CAPITAL FUND, LLC, an Illinois limited liability company (together with its permitted assigns, the “Buyer”). Capitalized terms used herein and not otherwise defined h
May 18, 2020	DEF 14A	Schedule 14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Definitive Proxy State
May 14, 2020	10-Q	Form 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 1-11388 VIVEVE MEDIC
May 14, 2020	EX-99.1	Viveve Reports First Quarter 2020 Financial Results and Provides Corporate Update Exhibit 99.1 Viveve Reports First Quarter 2020 Financial Results and Provides Corporate Update - First quarter continued to demonstrate success of the recurring revenue model - Organization focused on advancing stress urinary incontinence clinical strategy - Company to host conference call at 5:00 PM ET today ENGLEWOOD, CO – May 14, 2020 – Viveve Medical, Inc. (NASDAQ: VIVE), a medical technology
May 14, 2020	S-3	- FORM S-3 As filed with the Securities and Exchange Commission on May 14, 2020. Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-3 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 VIVEVE MEDICAL, INC. (Exact name of registrant as specified in its charter) Delaware 04-3153858 (State or other jurisdiction of incorporation or organization) (I.R.S. Empl
May 14, 2020	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 14, 2020 VIVEVE MEDICAL, INC. (Exact name of registrant as specified in its charter) Delaware 1-11388 04-3153858 (State or other jurisdiction of incorporation) (Commission File Nu
May 6, 2020	PRE 14A	- FORM PRE 14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy State
May 6, 2020	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): May 4, 2020 VIVEVE MEDICAL, INC. (Exact name of registrant as specified in its charter) Delaware 1-11388 04-3153858 (State or other jurisdiction of incorporation) (Commission File Num
April 24, 2020	8-K	Entry into a Material Definitive Agreement, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Financial Statements and Exhibits, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): April 21, 2020 VIVEVE MEDICAL, INC. (Exact name of registrant as specified in its charter) Delaware 1-11388 04-3153858 (State or other jurisdiction of incorporation) (Commission File
April 24, 2020	EX-10.1	Promissory Note, dated April 24, 2020, by and between Viveve, Inc. and Western Alliance Bank, an Arizona Corporation (29) Exhibit 10.1 U.S. Small Business Administration NOTE SBA Loan # 96956271-08 SBA Loan Name Viveve, Inc. Date 04/23/2020 Loan Amount $1,343,400.00 Interest Rate 1.00% per annum Borrower Viveve, Inc., a Delaware Corporation Operating Company N/A Lender Western Alliance Bank, an Arizona Corporation 1. PROMISE TO PAY: In return for the Loan, Borrower promises to pay to the order of Lender the amount of
April 17, 2020	EX-4.1	Form of Series A-2/B-2 Common Stock Purchase Warrant issued on April 20, 2020 (29) Exhibit 4.1 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTR
April 17, 2020	EX-10.1	Form of Inducement Letter (28) Exhibit 10.1 VIVEVE MEDICAL, INC. April , 2020 Holder of Common Stock Purchase Warrant Re: Inducement Offer to Exercise Common Stock Purchase Warrants Dear Holder: Viveve Medical, Inc. (the “Company”) is pleased to offer to you the opportunity to exercise all of the Series A Common Stock Purchase Warrants and/or the Series B Common Stock Purchase Warrants of the Company set forth on the signature
April 17, 2020	EX-99.3	Viveve Announces Update to Corporate Strategy Reconfirms plans for near-term focus on Stress Urinary Incontinence clinical strategy Announces plans to further reduce operating expenses and cash burn rate Strengthens balance sheet through warrant exer EX-99.3 6 ex181765.htm EXHIBIT 99.3 Exhibit 99.3 Viveve Announces Update to Corporate Strategy Reconfirms plans for near-term focus on Stress Urinary Incontinence clinical strategy Announces plans to further reduce operating expenses and cash burn rate Strengthens balance sheet through warrant exercise for approximately $3 million in proceeds ENGLEWOOD, CO – April 17, 2020 – Viveve Medical, Inc. (
April 17, 2020	EX-99.2	Viveve Announces Exercise of Warrants for $3 Million Gross Proceeds Exhibit 99.2 Viveve Announces Exercise of Warrants for $3 Million Gross Proceeds ENGLEWOOD, CO - (Marketwired) – April 17, 2020 - Viveve Medical, Inc. ("Viveve") (NASDAQ: VIVE), a medical technology company focused on women’s intimate health, today announced that it has entered into agreements with several institutional and accredited investors to exercise certain outstanding Series A warrants to
April 17, 2020	EX-99.1	Viveve Medical, Inc. 342 Inverness Drive South, Building B, Suite 250 Englewood, Colorado 80112 Exhibit 99.1 Viveve Medical, Inc. 342 Inverness Drive South, Building B, Suite 250 Englewood, Colorado 80112 April 15, 2020 VStock Transfer, LLC 18 Lafayette Place Woodmere, New York 11598 Attn: Young D. Kim, Esq. Re: Viveve Medical, Inc. Series A Warrants (CUSIP: 92852W 121) and Series B warrants (CUSIP: 92852W 113) Ladies and Gentlemen: Please be advised that, effective April 15, 2020, pursuant
April 17, 2020	8-K	Entry into a Material Definitive Agreement, Material Modification to Rights of Security Holders, Unregistered Sales of Equity Securities, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 15, 2020 VIVEVE MEDICAL, INC. (Exact name of registrant as specified in its charter) Delaware 1-11388 04-3153858 (State or other jurisdiction of incorporation) (Commission File
April 17, 2020	424B3	VIVEVE MEDICAL, INC. 978,202 Class A Units consisting of shares of common stock and warrants to purchase up to 1,956,404 shares of common stock and 5,473,410 Class B Units consisting of shares of Series A Preferred Stock and warrants to purchase up t Filed Pursuant to Rule 424(b)(3) Registration Nos. 333-233639 PROSPECTUS SUPPLEMENT NO. 1 DATED APRIL 17, 2020 (To Prospectus dated November 22, 2019) VIVEVE MEDICAL, INC. 978,202 Class A Units consisting of shares of common stock and warrants to purchase up to 1,956,404 shares of common stock and 5,473,410 Class B Units consisting of shares of Series A Preferred Stock and warrants to purchase up
April 16, 2020	EX-99.1	Viveve Announces Approval of Viveve 2.0 System in Canada Viveve 2.0 System now available throughout North America, Asia, and over 30 European countries Exhibit 99.1 Viveve Announces Approval of Viveve 2.0 System in Canada Viveve 2.0 System now available throughout North America, Asia, and over 30 European countries ENGLEWOOD, CO – April 16, 2020 - Viveve Medical, Inc. (NASDAQ: VIVE), a medical technology company focused on women's intimate health, today announced it has received regulatory clearance from the Canadian Ministry of Health for the Co
April 16, 2020	8-K	Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 16, 2020 VIVEVE MEDICAL, INC. (Exact name of registrant as specified in its charter) Delaware 1-11388 04-3153858 (State or other jurisdiction of incorporation) (Commission File
April 15, 2020	8-K	Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 15, 2020 VIVEVE MEDICAL, INC. (Exact name of registrant as specified in its charter) Delaware 1-11388 04-3153858 (State or other jurisdiction of incorporation) (Commission File
April 15, 2020	EX-99.1	Viveve Resubmits U.S. Investigational Device Exemption to FDA to Conduct New PURSUIT Trial for Improvement of Stress Urinary Incontinence Proposed pivotal trial reinforces the company’s strategic pursuit of label expansion for Cryogen-cooled, Monopol Exhibit 99.1 Viveve Resubmits U.S. Investigational Device Exemption to FDA to Conduct New PURSUIT Trial for Improvement of Stress Urinary Incontinence Proposed pivotal trial reinforces the company’s strategic pursuit of label expansion for Cryogen-cooled, Monopolar Radiofrequency (CMRF) technology in SUI indication ENGLEWOOD, CO – April 15, 2020 – Viveve Medical, Inc. (NASDAQ: VIVE), a medical tec
April 9, 2020	EX-99.1	Viveve Announces Topline Results from Pivotal U.S. VIVEVE II Trial for Improvement of Sexual Function in Women Exhibit 99.1 Viveve Announces Topline Results from Pivotal U.S. VIVEVE II Trial for Improvement of Sexual Function in Women ENGLEWOOD, CO – April 9, 2020 – Viveve Medical, Inc. (NASDAQ: VIVE), a medical technology company focused on women's intimate health, today announced topline results from the VIVEVE II clinical trial. VIVEVE II is a multicenter, randomized, double-blinded, sham-controlled stu
April 9, 2020	8-K	Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 9, 2020 VIVEVE MEDICAL, INC. (Exact name of registrant as specified in its charter) Delaware 1-11388 04-3153858 (State or other jurisdiction of incorporation) (Commission File N
March 26, 2020	EX-99.1	Viveve Announces Clearance of Next Generation 2.0 System in Taiwan Exhibit 99.1 Viveve Announces Clearance of Next Generation 2.0 System in Taiwan - Viveve 2.0 cryogen-cool monopolar radiofrequency technology and consumable treatment tips are now available in the U.S., China, Hong Kong, South Korea, Taiwan and more than 30 European countries ENGLEWOOD, CO – March 26, 2020 – Viveve Medical, Inc. (NASDAQ-VIVE), a medical technology company focused on women's intima
March 26, 2020	8-K	Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 26, 2020 VIVEVE MEDICAL, INC. (Exact name of registrant as specified in its charter) Delaware 1-11388 04-3153858 (State or other jurisdiction of incorporation) (Commission File
March 19, 2020	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 19, 2020 VIVEVE MEDICAL, INC. (Exact name of registrant as specified in its charter) Delaware 1-11388 04-3153858 (State or other jurisdiction of incorporation) (Commission File
March 19, 2020	S-8	VIVE / Viveve Medical, Inc. S-8 - - FORM S-8 As filed with the Securities and Exchange Commission on March 19, 2020 Registration No.
March 19, 2020	10-K	Form 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2019 or ☐ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from .
March 19, 2020	EX-99.1	Viveve Reports Full Year 2019 Financial Results Exhibit 99.1 Viveve Reports Full Year 2019 Financial Results - Company completes successful U.S. commercial transition from traditional capital sales model to recurring revenue rental model - Landmark pivotal sexual function trial (VIVEVE II) completed with data readout scheduled for April - SUI clinical development program with short-term feasibility study continues to advance - Company to host c
March 19, 2020	EX-4.17	Description of Securities (31) Exhibit 4.17 DESCRIPTION OF THE REGISTRANT’S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 Viveve Medical, Inc. (“Viveve”) has one class of securities registered under Section 12 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”): common stock, par value $0.0001 per share (the “common stock”). DESCRIPTION OF COMMON STOCK The following summ
March 12, 2020	8-K	Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 12, 2020 VIVEVE MEDICAL, INC. (Exact name of registrant as specified in its charter) Delaware 1-11388 04-3153858 (State or other jurisdiction of incorporation) (Commission File
March 12, 2020	EX-99.1	Viveve Announces Completion of VIVEVE II Pivotal FDA Clinical Trial for Improvement of Sexual Function Exhibit 99.1 Viveve Announces Completion of VIVEVE II Pivotal FDA Clinical Trial for Improvement of Sexual Function - Unblinded top-line results of the 12-month U.S. study anticipated in April - If positive, results may support a 2020 marketing application for an expanded U.S. indication for improvement of sexual function in women ENGLEWOOD, CO – March 12, 2020 – Viveve Medical, Inc. (NASDAQ: VIVE
March 4, 2020	8-K	Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 4, 2020 VIVEVE MEDICAL, INC. (Exact name of registrant as specified in its charter) Delaware 1-11388 04-3153858 (State or other jurisdiction of incorporation) (Commission File N
March 4, 2020	EX-99.1	Viveve Completes Enrollment in Short-Term Feasibility Study for Stress Urinary Incontinence Exhibit 99.1 Viveve Completes Enrollment in Short-Term Feasibility Study for Stress Urinary Incontinence - Three-arm study compares Viveve’s Cryogen-cooled Monopolar Radiofrequency (CMRF) treatment and cryogen-only sham to inert sham treatment - Topline results anticipated in third quarter 2020 Englewood, CO – March 4, 2020 – Viveve Medical, Inc. (NASDAQ: VIVE), a medical technology company focuse
February 14, 2020	EX-1	Joint Filing Statement Pursuant to Rule 13d-1(k)(1) Exhibit 1 Joint Filing Statement Pursuant to Rule 13d-1(k)(1) The undersigned hereby consent and agree to the joint filing of Schedule 13G Amendment No.
February 14, 2020	SC 13G/A	VIVMF / Viveve Medical, Inc. / RTW INVESTMENTS, LLC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No.
February 13, 2020	SC 13G	VIVMF / Viveve Medical, Inc. / Capital Royalty L.p. - SCHEDULE 13G FOR VIVEVE MEDICAL, INC. BY CR GROUP L.P. Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b),(c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2 (Amendment No. ) * Viveve Medical, Inc. (Name of Issuer) Common Stock, $0.0001 par value (Title of Class of Securities) 92852W303 (CUSIP Number) November 26, 2019 (Date of Even
February 13, 2020	SC 13G/A	VIVMF / Viveve Medical, Inc. / Hood River Capital Management LLC - AMENDMENT NO. 1 Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* VIVEVE MEDICAL INC. (Name of Issuer) Common Stock (Title of Class of Securities) 92852W204 (CUSIP Number) June 30, 2019 (Date of Event Which Requires Filing of This Statement) Check the appropriate box to designate the rule pursuant to which this Sched
February 11, 2020	SC 13G/A	VIVMF / Viveve Medical, Inc. / UBS Group AG - SC 13G/A Passive Investment SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* Viveve Medical, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 92852W303 (CUSIP Number) December 31, 2019 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to whic
February 10, 2020	SC 13G/A	VIVMF / Viveve Medical, Inc. / CVI Investments, Inc. - SC 13G/A Passive Investment CUSIP No: 92852W303 SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.13d-1(b), (c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13d-2. (Amendment No. 1)* Viveve Medical, Inc. (Name of Issuer) Common Stock, $0.0001 par value per share (Title of Class of Securities) 92852W303 (CUSIP Number
February 7, 2020	SC 13G	VIVMF / Viveve Medical, Inc. / Hudson Bay Capital Management LP - VIVE 13G Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No.)* Viveve Medical, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 92852W303 (CUSIP Number) December 31, 2019 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to
January 14, 2020	EX-99.1	Viveve Initiates Enrollment of its Short-Term Feasibility Study in Stress Urinary Incontinence Exhibit 99.1 Viveve Initiates Enrollment of its Short-Term Feasibility Study in Stress Urinary Incontinence - Three-arm, three-month study will compare Viveve’s cryogen-cooled monopolar radiofrequency (CMRF) treatment and cryogen-only sham to inert sham treatment ENGLEWOOD, CO – January 14, 2020 – Viveve Medical, Inc. (NASDAQ: VIVE), a medical technology company focused on women’s intimate health,
January 14, 2020	8-K	Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 14, 2020 VIVEVE MEDICAL, INC. (Exact name of registrant as specified in its charter) Delaware 1-11388 04-3153858 (State or other jurisdiction of incorporation) (Commission Fil
December 31, 2019	EX-99.1	Viveve Announces Compliance with Nasdaq Listing Rules Exhibit 99.1 Viveve Announces Compliance with Nasdaq Listing Rules ENGLEWOOD, CO – December 31, 2019 – Viveve Medical, Inc. (NASDAQ: VIVE), a medical technology company focused on women’s intimate health, announced today that it has been notified by Nasdaq that Viveve has regained compliance with the Nasdaq Capital Market continued listing requirements, the scheduled hearing before the Nasdaq Hear
December 31, 2019	8-K	Unregistered Sales of Equity Securities, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 30, 2019 VIVEVE MEDICAL, INC. (Exact name of registrant as specified in its charter) Delaware 1-11388 04-3153858 (State or other jurisdiction of incorporation) (Commission Fi
December 18, 2019	EX-99.1	Viveve Announces Authorization to Initiate Short-Term Feasibility Study in Stress Urinary Incontinence from Canadian Ministry of Health Exhibit 99.1 Viveve Announces Authorization to Initiate Short-Term Feasibility Study in Stress Urinary Incontinence from Canadian Ministry of Health - Three-arm, three-month study will compare Viveve’s cryogen-cooled monopolar radiofrequency (CMRF) treatment and cryogen-only sham to an inert sham treatment ENGLEWOOD, CO – December 18, 2019 – Viveve Medical, Inc. (NASDAQ: VIVE), a medical technolog
December 18, 2019	8-K	Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 18, 2019 VIVEVE MEDICAL, INC. (Exact name of registrant as specified in its charter) Delaware 1-11388 04-3153858 (State or other jurisdiction of incorporation) (Commission Fi
December 10, 2019	8-K	Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 10, 2019 VIVEVE MEDICAL, INC. (Exact name of registrant as specified in its charter) Delaware 1-11388 04-3153858 (State or other jurisdiction of incorporation) (Commission Fi

VIVE / Viveve Medical, Inc. - SEC Filings, Annual Report, Proxy Statement

Basic Stats

SEC Filings

SEC Filings (Chronological Order)